IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ)
CUSIP: 449778109
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 73,755,848
- Total 13F shares
- 23,591,882
- Share change
- -2,591,167
- Total reported value
- $24,769,965
- Price per share
- $1.05
- Number of holders
- 19
- Value change
- -$2,959,503
- Number of buys
- 8
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 449778109?
CUSIP 449778109 identifies IOBTQ - IO Biotech, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 449778109:
Top shareholders of IOBTQ - IO Biotech, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Invest A/s Lundbeckfond |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
21,851,920
mixed-class rows
|
$14,438,960 | — | 09 Aug 2023 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
12,346,878
mixed-class rows
|
$9,510,598 | — | 09 Aug 2023 | |
| Vivo Capital, LLC |
13F
|
Company |
8.4%
|
6,173,439
|
$7,222,924 | — | 30 Jun 2024 | |
| Novo Holdings A/S |
3/4/5
13F
|
10%+ Owner · Company |
6%
from 13F
|
6,823,584
mixed-class rows
|
$5,709,989 | — | 25 Jul 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
4.9%
|
3,640,015
|
$4,258,818 | — | 30 Jun 2024 | |
| HBM Healthcare Investments (Cayman) Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,690,545
|
$2,784,714 | — | 09 Nov 2021 | |
| PFM Health Sciences, LP |
13F
|
Company |
3.2%
|
2,341,107
|
$2,739,095 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2.9%
|
2,105,262
|
$2,463,156 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.7%
|
1,972,343
|
$2,307,641 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.2%
|
1,651,515
|
$1,932,273 | — | 30 Jun 2024 | |
| Claus A. Andersson |
3/4/5
|
Director |
—
class O/S missing
|
1,791,490
|
$1,854,192 | — | 09 Nov 2021 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
2.1%
|
1,545,000
|
$1,807,650 | — | 30 Jun 2024 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
1.2%
|
864,197
|
$1,011,110 | — | 30 Jun 2024 | |
| Kurma Partners |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
623,428
|
$645,248 | — | 09 Aug 2023 | |
| Logos Global Management LP |
13F
|
Company |
0.67%
|
493,827
|
$577,778 | — | 30 Jun 2024 | |
| Vanessa Malier |
3/4/5
|
Director |
—
class O/S missing
|
430,477
|
$445,544 | — | 09 Nov 2021 | |
| FMR LLC |
13F
|
Company |
0.43%
|
314,600
|
$368,082 | — | 30 Jun 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.26%
|
192,670
|
$225,424 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.25%
|
180,800
|
$211,536 | — | 30 Jun 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.17%
|
124,623
|
$145,809 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.12%
|
86,894
|
$101,666 | — | 30 Jun 2024 | |
| Marex Group plc |
13F
|
Company |
0.06%
|
45,000
|
$52,650 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
33,307
|
$38,969 | — | 30 Jun 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.04%
|
26,555
|
$31,069 | — | 30 Jun 2024 | |
| Redwood Wealth Management Group, LLC |
13F
|
Company |
0.01%
|
4,166
|
$4,874 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
3,280
|
$3,838 | — | 30 Jun 2024 | |
| Eva Ehrnrooth |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Muhammad Al-Hajj |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
120,000
|
— | — | 20 Mar 2023 | |
| Keith A. Vendola |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
69,469
|
— | — | 04 Nov 2021 | |
| Jack Nielsen |
3/4/5
|
Director |
—
class O/S missing
|
41,533
|
— | — | 08 Jun 2023 |
Institutional Holders of IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ) as of Q3 2024
As of 30 Sep 2024,
IO Biotech, Inc. - Common Stock, par value $0.001 per share (IOBTQ) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,591,882 shares.
The largest 10 holders included
Vivo Capital, LLC, Samsara BioCapital, LLC, Novo Holdings A/S, PFM Health Sciences, LP, MORGAN STANLEY, MARSHALL WACE, LLP, BANK OF AMERICA CORP /DE/, Pivotal bioVenture Partners Investment Advisor LLC, Logos Global Management LP, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
20
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
19
Q3 2024 holders
19
Holder diff
0
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.